Apotex launches Apo‑Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada
TORONTO, May 14, 2026 /PRNewswire/ – Apotex Inc. (“Apotex” or the “Company”), the largest Canadian‑based global health company,…
Apotex becomes the first Canadian‑based pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic®
TORONTO, May 1, 2026 /PRNewswire/ – Apotex Inc. (“Apotex” or the “Company”), Canada’s largest Canadian‑based global health company,…